3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
4
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
17
Brain Neoplasms
5
Neoplasm Metastasis
4
Neoplasms
3
Meningeal Neoplasms
3
Triple Negative Breast Neoplasms
2
Rectal Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Pathologic Complete Response
1
Multiple Myeloma
1
Metastatic Breast Cancer With a Isolated Brain Progression
1
Meningeal Carcinomatosis
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Breast Cancer
1
Central Nervous System Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Anatomic Stage II Breast Cancer AJCC v8
1
Anatomic Stage IA Breast Cancer AJCC v8
1
Adenocarcinoma
1
Interventions
Trastuzumab
19
pyrotinib
14
pertuzumab
8
Docetaxel
7
Paclitaxel
6
Capecitabine
4
Carboplatin
3
neratinib
2
Protons
2
Neoadjuvant Therapy
2
Fulvestrant
2
Ado-Trastuzumab Emtansine
2
tucatinib
1
trastuzumab deruxtecan
1
pegfilgrastim
1
palbociclib
1
inavolisib
1
exemestane
1
envafolimab
1
dalpiciclib
1
atezolizumab
1
Taxoids
1
Metformin
1
Leuprolide
1
Letrozole
1
Isovaleryl-CoA Dehydrogenase
1
Goserelin
1
Genetic Testing
1
Fluorodeoxyglucose F18
1
Enfuvirtide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
HER2-positive Breast Cancer
×
tucatinib
×
Clear all
NCT05955170
2025-03-27
TUC-TOC
Institut Curie
Phase 2
Recruiting
66 enrolled